Your Source for BioScience Venture Capital Data
  • SEARCH THE OnBioVC DATABASE:

  • OnBioVC NEWS:

    - OnBioVC 4Q11 Trend Analysis, now available
    - OnBioVC 1Q12 White Paper, now available
    - OnBioVC 1Q12 Trend Analysis, coming soon

  • Photobucket

  • FDA Registered Contract Manufacturer

Millions of Technologies and Inventors from Hundreds of Universities and Research Institutes Now Accessible in a Single Search Boulder, CO April 22, 2013 – Collective IP, Inc., the global leader in innovation intelligence, announced today the launch of CollectiveIP.com, a new approach to search for technology transfer asset identification. The Collective IP search engine gives [...]

Are you attending the 2013 BIO International Convention and have Technology Transfer, Business Development and/or In-/Out-Licensing on your mind? Then come take a break from the BIO convention floor, rest your feet, relax and enjoy some cocktails and delicious snacks and deserts at Shaw’s, a jazzy, sophisticated, seafood restaurant and carefree, lively oyster bar. DIRECTIONS:Take [...]

Healthrageous (Boston, MA), a commercial-stage Health IT provider of self-management solutions, closed a $6.5M Series B financing. Participants include North Bridge Venture Partners, Egan-Managed Capital and Long River Ventures. Collective IP | The Most Comprehensive and Accurate View of Global Innovation and Organization of the International Technology Transfer Office Ecosystem Request Collective IP Account Access HERE

Aclaris Therapeutics (Malvern, PA), a preclinical-stage pharmaceutical company focused on topical dermatological therapies, closed a $21M Series A financing. Participants include Vivo Ventures, Fidelity Biosciences and Sofinnova Ventures. Collective IP | The Most Comprehensive and Accurate View of Global Innovation and Organization of the International Technology Transfer Office Ecosystem Request Collective IP Account Access HERE

Mirna Therapeutics (Austin, TX), a pre-clinical biologics company developing micro-RNA directed oncology therapies, closed a $34.5M Series C financing. Participants include Sofinnova Ventures, New Enterprise Associates, Pfizer Ventures, Osage University Partners and Correlation Ventures. ___________ Collective IP | The Most Comprehensive and Accurate View of Global Innovation and Organization of the International Technology Transfer Office Ecosystem [...]

What has been going on with OnBioVC the last few months? Well, I am excited to inform you of a new application we have developed, Collective IP. We are now seeking beta-testers for this novel innovation identification platform, please read on to understand our value proposition and to determine if you may qualify to participate. [...]

Dear Dedicated OnBioVC Subscribers, We sure are behind on posting deals and publishing our quarterly OnBioVC Trend Analysis. The reinforcements have been summoned and we are getting back to bringing you the only dedicated source of bioscience deal data. Your ongoing support is appreciated. Stay tuned as we turn the spigot back on. Thanx! – [...]

A heated debate is raging regarding who exactly were the recipients of the fourth quarter spike in venture dollars – many believe that innovation has recently suffered from a lack of funding while reconstituted products and late-stage assets have benefited from the lions share of risk capital. We are pleased to present our 4Q11 Series [...]

The 4Q11 & 2011 OnBioVC Trend Analysis study is available for download [HERE]. OnBioVC the industry leader in organizing and reporting life science private venture financings, today announced the release of its 2011 Trend Analysis. The 4Q11 OnBioVC Trend Analysis tracked, in aggregate, 93 biopharma, diagnostic, device, medical-IT and biofuel venture financings totaling $1,662.8M, compared [...]

OnBioVC has blacked out its service for 24 hours on January 18th to raise awareness about legislation being proposed by the U.S. Congress — the Stop Online Piracy Act (SOPA) in the U.S. House of Representatives, and the Protect IP Act (PIPA) in the U.S. Senate — and to encourage readers to speak out against [...]

OnBioVC is seeking an Intern for the spring semester (possibly longer). If you (or a student you know) is interested in learning more about the intersection of bioscience and business (and making a meaningful contribution in the process) then please forward your resume me, Adam Rubenstein, at arubenstein@rnaventures.com.

Calibrate your expectations to receive the 4Q11 and 2011 OnBioVC Trend Analysis in January. Thanks to many of our dedicated readers who have checked in with us during a quiescent period in the late fall. Some interesting plans are in the works – based upon your feedback on the recent survey – more details to [...]

OnBioVC continues to illuminate a deeply concerning financing trend observed over the last several years of aggregated data; one may term the resultant effect of this discernable development as an erosion in U.S.-based biomedical innovation. The metric invoked to quantify such bold nomenclature is simply the decline in first-time, Series A, institutional financings. With fewer [...]

« Previous Entries  Next Page »

to top of page...